IMG 0313


Life Science Advisor


Investment Advisory Panel

Dr Vijay Barathan MD


Life Science Partner
GM&C Life Sciences Fund

T: 01625 344 300

M: 07823 350820

Vijay is a Life Science Partner with Catapult’s GM&C Life Sciences Fund, which he joined in September 2016 to lead and manage investments across Life Sciences. Vijay was most recently Chief Investment Officer at NetScientific plc, a listed healthcare IP commercialisation company focused on chronic diseases through digital health, diagnostics and therapeutics investments.

Vijay was previously a Healthcare Investment Banker at Peel Hunt and Piper Jaffray, looking after listed healthcare clients as well as undertaking IPO, M&A, private placement and secondary fundraising transactions.

Vijay began his career in medicine and worked in various London and South East hospitals. He qualified from Guy’s Kings and St Thomas Medical School, in London, and holds a degree in Medicine and a BSc in Development Neurobiology.

Duncan Cameron

Chief Financial Officer

T: 0116 238 8200
M: 07753 353 424

Duncan is Catapult’s CFO and directly manages a number of portfolio companies, as well as serving on the three Catapult Investment Committees. He has nearly 25 years’ experience within the private equity industry since joining NatWest’s venture capital business in 1989. Duncan has experience of making, managing and realising investments across industry sectors including automotive design, transportation, professional services, software, renewable energy and telecoms.

Following a period spent leading a research and origination team within NatWest’s London office, Duncan relocated to Nottingham in 1996 to help launch a NatWest fund focussed on small / mid-market transactions where he had responsibility for investment across the Midlands.  Following a decision in 2002 by NatWest to focus on larger transactions, Duncan spent a number of years working as a non-executive director and consultant, mainly supporting institutionally backed companies. This period also included work with The Salvation Army on a sustainable income generation fund which saw Duncan involved in evaluating projects in a number of countries including Latvia, Bangladesh and Paraguay.   

Duncan’s first involvement with Catapult came in early 2007 when he was asked to chair the investment committee of the new Catapult Growth Fund.  Later that year he took on an executive role with the business, managing a number of investments and also fulfilling the FD and Deputy MD roles.

Duncan is a Chartered Accountant (ICAS) and holds a B.A. in Business and Administration from Strathclyde University. 

Rob Carroll


T: 0116 238 8200
M: 07976 226 252

Rob is a Director of Catapult Ventures and chairs Catapult’s four Investment Committees. Prior to September 2013, Rob was Managing Director of Catapult, which he started in October 1999. He previously worked at 3i plc in Leicester and London and ECI in the Midlands.

Rob is a Non-Executive Director of Replay Limited in Newark. He has lectured at Nottingham University Business School since 2011 in Venture Capital and Private Equity and was appointed Honorary Professor in August 2013 and Professor of Practice in July 2016. He was appointed to the Board of Lord Young's Small Business Charter in 2016.

Rob is an honours graduate with an Upper Second Class Honours degree in Pharmacy from Kings College, London.  He holds an MBA from Bradford University Management School. He also holds an NLP practitioner qualification from the International NLP Trainers Association.

Sarah Cooper

Office Manager, East Midlands Office

Tel: 0116 238 8200

Sarah Cooper is the Office Manager based at Catapult's Head Office. Sarah joined Catapult in January 2006 having previously worked for an actuarial firm for eight years and eight years in Ernst & Young's Corporate Finance Department in Birmingham. In addition to general administration, Sarah assists the Financial Controller.

Dr Tony Flinn

Venture Partner
GM&C Life Sciences Fund

Tony is a Venture Partner with Catapult’s GM&C Life Sciences Fund, where he helps assess service company (CRO) investment opportunities and works with the Fund’s smaller investments to help companies successfully grow.

Tony is a well-known non-executive director and motivational speaker who co-founded Onyx Scientific in 2000 to offer contract chemistry services to many of the world’s leading drug developers. He grew the business to become one the fastest growing technology companies in the UK, employing more than 60 staff at its peak, managed an MBO in 2007, and ultimately sold the business to IPCA, a large Indian pharmaceutical service provider, in 2011.

Tony began his career as a Post-Doctoral Research Fellow, first with the Cancer Research Institute, and then with Oxford University. After a period as a Research Chemist with Dow Chemical he began the first of several business development roles.   

Tony holds a First Class BSc in Chemistry and PhD in Synthetic Organic Chemistry, both from Heriot-Watt University. He is a Fellow of the Royal Society of Chemistry and a Chartered Chemist (FRSC CChem).

Anne Freeman

PA to Chairman

Tel: 0116 238 8200

Anne Freeman is PA to Laurence Vaughan, Chairman. She is also involved in various aspects of Opus Ventures, which she joined at inception in 2003.

Prior to Opus, Anne spent 7 years as personal assistant to the Chairman, CEO and Finance Director of Sytner Group. Before joining Sytner, Anne spent 15 years as a Senior Secretary at PwC East Midlands working for partners in the audit and advisory functions. Anne speaks basic German.

Dr Hamish Graham MD

Medical Advisor

Hamish joined the Catapult team in June 2015, initially as an MBA Summer Intern. He is a member of the Royal College of Surgeons England with many year’s clinical experience and holds degrees in Medicine (University of Sheffield), Healthcare Ethics & Law (University of Manchester) and an MBA from Manchester Business School, with a focus on Venture Capital and Private Equity.

Hamish has worked in a variety of settings from Somalia to Sheffield both in hospital and pre-hospital settings. While Co-Chairing the Junior Doctors leadership group at Guy’s & St. Thomas’ hospitals, London, he supported members tackling the strategic challenges the trust faced working alongside the senior leadership team. He has had broad engagement with Quality Improvement projects at district general hospitals and major trauma centres.

Since completing his MBA in 2016, Hamish has built an active portfolio of consulting and business interests. He also continues to work as a Trackside Doctor at Brands Hatch Motor Circuit.

Dr Gareth King


Life Science Partner
GM&C Life Sciences Fund

T: 01625 344 300

M: 07720 051988


Gareth is a Life Science Partner with Catapult’s GM&C Life Sciences Fund, where he has been leading and managing investments since the Fund launched in late 2015.

Gareth was most recently CEO of Critical Pharmaceuticals, a clinical stage biotechnology company utilising a proprietary drug delivery technology to develop a pipeline of unique biological drug products, which raised >£4m from investors including Catapult Ventures and the Welcome Trust. Gareth was previously VP Business Development at Pharmaceutical Profiles, which he joined from Manchester-based start-up Cyprotex, where he was Commercial Director.

Gareth began his career in Boston, USA as a Research Fellow at Harvard Medical School. He moved back to the UK and was based at Alderley Park for over 3 years as Bioinformatics Project Manager with AstraZeneca, before joining California-based genomics company Incyte.

Gareth holds an BSc in Microbiology from Sheffield University and a PhD in Molecular Genetics from Edinburgh University.

Corinne Lawrence

Group Financial Controller

Tel: 0116 238 8200

Corinne Lawrence is Group Financial Controller of Catapult Ventures and works across the three Catapult funds and Opus Ventures. She joined the company in January 2002. Prior to this, Corinne worked for seven years as a Portfolio Executive at 3i plc, in Leicester and Nottingham.

Corinne previously worked in audit, specialising in regulated clients and qualified as a Chartered Accountant in 1993.

Jonathan Lowe

Head of Investor Relations

T. 0116 238 8200
M. 07527 315786

Jonathan is an Investment Director and Head of Investor Relations at Catapult Ventures, having joined the company in August 2013.

Jonathan previously worked as a Portfolio Director at Capital for Enterprise Ltd, the Government-owned company managing £1 billion of Government investments in a range of venture capital funds. Prior to CfEL, Jonathan was Head of Business Investment at East Midlands Development Agency, where he led the development of new loan and equity funds and the delivery of two multi-million pound SME grant programmes. He was also a member of the Investment Advisory Committee of the Lachesis Seed Fund.

Jonathan began his career at NatWest in Nottingham, where he managed head office credit teams and was a business relationship manager.

Jonathan holds a BA (Hons) in Politics from the University of Leicester.

Natalie Melvin

Portfolio Assistant / Marketing Executive

Tel  0116 238 8200

Natalie Melvin is based at Catapult's Head Office and is responsible for portfolio administration and marketing activity.  

Natalie worked as a Portfolio Assistant and Executive Secretary at 3i plc and has ten years' experience in venture capital administration.  Previously Natalie worked as an Executive Secretary in the health service and the newspaper industry.

Natalie holds a BA Hons degree in Italian from the University of Hull.

Sam Bailey

Office Manager, Alderley Park 

Tel: 01625 344300

Sam Bailey is the Office Manager based at Catapult's Alderley Park office. Sam joined Catapult in January 2016 having previously worked for ICI, Zeneca and AstraZeneca for 23 years in administration and quality assurance and spent 18 months working for BioHub at Alderley Park.

Laurence Vaughan


T: 0116 238 8200

Laurence has been Chairman of Catapult Ventures since September 2013 and is the Founding Partner of Opus Ventures. 

Laurence began his career with PwC in audit and consulting before joining a client as Financial Director. In 1993 he joined Sytner where as CEO he led the team that grew the company from a single BMW dealership in Nottingham to a luxury car group with around £1bn revenues by 1997 when it listed on the London Stock Exchange. Sytner was bought by US-based Penske Group in 2002 and Laurence joined the main board before becoming Sytner’s non-executive Chairman and founding Opus Ventures. Today Sytner has more than 140 prestige dealerships around the UK, including Audi, Bentley, Ferrari, Lamborghini, Land Rover, Lexus, Maserati, McLaren, Porsche and Rolls Royce. It has revenues in excess of £3bn and is the UK’s most profitable car dealership group.

In 2006 Laurence was appointed Chairman of Alchemy-backed Civica plc, which he helped float on AIM. He stepped down in late 2008 following Civica’s acquisition by 3i plc and their decision to delist the business. Laurence is also Chairman of r2c Online Ltd, a Catapult portfolio company specialising in compliance and invoicing systems for truck, coach and haulage operators. In August 2015 Laurence was appointed Chairman of Idox plc. Laurence was also Executive Chairman of Anglian Home Improvements from September 2013 to March 2015.

Laurence holds a BA from Durham University and is a chartered accountant. 

Ed Wass

Chief Investment Officer

T: 0116 238 8200
M: 07771 596 007

Ed is CIO at Catapult Ventures, where he oversees investment processes and portfolio valuations. He joined the firm in March 2009 and is also Compliance Officer.

Ed has over 10 years’ experience of both managing and investing in SMEs.  He started his career with PwC in London which included five years working in business recovery. He then participated in the BIMBO of DS-J, a Leicester based marketing agency, where he was the Finance Director for five years. Ed successfully led the negotiations of the sale of the business to Partners Andrews Aldridge in 2007. Immediately prior to joining Catapult he held a number of interim FD roles, including The CarbonNeutral Company, backed by Zouk Ventures, where he advised on its merger with US-based carbon management business, Greenlife.

Ed holds a BA from The University of Nottingham and is a Chartered Accountant. 

Dr David Whitcombe

Venture Partner
GM&C Life Sciences Fund

David is a Venture Partner with Catapult’s GM&C Life Sciences Fund, where he assesses investment opportunities and works with the Fund’s smaller investments to help companies successfully grow.

David is a well-known consultant and non-executive director/Chairman who co-founded DxS Diagnostics in 2000 to exploit a personalised medicine technology he had invented while with AstraZeneca Diagnostics. DxS was sold to Qiagen in September 2009 for in excess of £100m. Prior to DxS, David was Head of Technology Development at AstraZenica Diagnostics for four years where he led a team of up to 15 scientists working on new genome technologies.

David began his career as a Post-Doctoral Fellow with Warwick University Department of Biological Sciences, before joining Cambridge University Department of Medicine as a Senior Post-Doctoral Fellow where he researched the Genetics of Human Disease for six years.

David holds a First Class BSc in Genetics from the University of York and PhD in Biochemistry/Molecular Biology from the University of Leicester.

Nick Wright

Chief Executive Officer

Tel: 0116 238 8200

M: 07949 525753

Nick became Chief Executive Officer of Catapult Ventures in September 2013 and oversees the day to day running of the business.

Nick has over 10 years’ experience running investment funds and has managed more than 50 transactions. Most recently he managed an early stage venture capital fund investing in Midlands businesses and prior to that he was Commercial Director of a £6m proof of concept fund set up by Stanford University in California and the University of Edinburgh, where he also founded two MSc entrepreneurship courses.

Nick previously established the technology research team at Fast Track where he launched The Sunday Times Tech Track 100 business supplement. He began his career with Financial Times when he joined and later ran China's first foreign Internet joint venture, before returning to London as a consultant to help FT Group assess their internet strategy in the Far East. He has also had stints with Information Age (bought by Vitesse Media) and internet incubator GorillaPark, headquartered in Amsterdam.

In 2005 Nick co-founded CereProc, now a leading speech synthesis company and he has been an advisor to investment bank GP Bullhound since its inception. He was also an advisor to, one of the first citizen media companies, from initial trading until acquisition by Getty Images in 2007. Nick has also spent time on the advisory board of UnLtd Ventures, a £100m social entrepreneurship fund financed by the National Lottery.

Nick holds a BSc from the London School of Economics and an Advanced Diploma in Computing from Kellogg College, University of Oxford. He speaks basic Chinese.

From our portfolio


Medical Devices

viewview our portfolio

Contact us

Alderley Park
Alderley Edge
SK10 4TG

Tel: 01625 344300